The Business Combination is based on an agreed equity valuation of the Company of NOK 89.5 million and of Zelluna of NOK 384.8 million, prior to injection of new equity through the Private Placement.
ALKemist Bio, a biotechnology company dedicated to transforming the treatment of ALK-positive cancers, today announced the appointment of Dr. Adi Hoess to the company’s Board as an independent ...